Study design
AML
BRIGHT AML 1019 comprised two global, double-blind, phase 3 studies (NCT03416179). Details of the study design, including full eligibility criteria, were previously published [Adults were eligible if they had untreated AML (defined according to the World Health Organization 2016 Classification [The study complied with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. The protocol was approved by the institutional review boards of the participating institutions, and all patients provided signed informed consent.